Dialysis world news


Data released today show performance of Minnesota dialysis centers - St. Cloud Times
St. Cloud Times
“The single most important part of this is the expected mortality,” said Dr. James McCarthy, chair of the division of nephrology and hypertension at the Mayo Clinic in Rochester. “I would want to have some idea of the total impact of the practices in

...

 
Opsona Therapeutics announces the issuance of new patent from the European ... - MarketWatch (press release)

DUBLIN, Apr 17, 2012 (BUSINESS WIRE) -- Opsona Therapeutics, the innate immune drug development company, today announced that the European Patent Office has issued EP Patent 1,664,118 which covers an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof.

TLR-2 plays an important role in the induction and progression of a number of non-pathogen associated inflammatory conditions including ischemia reperfusion injury (delayed graft function in renal transplantation, myocardial infarct), certain cancer, autoimmune diseases, diabetes, Alzheimer's disease and atherosclerosis.

TLR-2 is one of the key structures of the innate immune system and is part of the first line defense against microbial organisms. Upon stimulation it induces and propagates inflammation. TLR-2 is activated through so called external danger signals (microbial cell wall components) as well as through so called internal danger signals resulting from tissue injury.

This patent describes a cross reactive antibody which specifically blocks mammalian TLR-2 and further provides for a pharmaceutical composition for the treatment of various inflammatory conditions. The recently issued patent is assigned to the Technische Universitat Munchen (TUM) and Amgen Inc, and is exclusively licensed by Opsona Therapeutics.

Using the TUM/Amgen license, Opsona has developed a clinical anti-TLR-2 antibody candidate, termed 'OPN-305'. OPN-305 is a humanised IgG4 monoclonal antibody (MAb) antagonizing TLR-2 and is under development as a treatment for the prevention of Delayed Graft Function (DGF) following renal transplantation, in addition to other therapeutic indications.

Opsona has successfully conducted a phase 1 clinical trial in healthy volunteers with its lead drug candidate OPN-305. This is the first-in-human study with OPN-305 and also represents the first clinical study for an anti-TLR-2 drug candidate.

Following successful completion of the phase 1 trial, the company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012.

Commenting on today's announcement, Mary Reilly VP Pharmaceutical Development and Operations of Opsona Therapeutics said, "The issuance of this patent is an important milestone in the development of Opsona's TLR-2 intellectual property portfolio and will facilitate market exclusivity for the use of OPN-305 in the ever expanding area of TLR-2 mediated diseases."

-ends-

About Opsona Therapeutics

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin. Opsona's lead product, a fully human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR-2) has demonstrated activity in a number of animal models and was recently tested in a phase 1 clinical trial in healthy volunteers. Following successful completion of the phase 1 trial, the company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012. In May 2009 the company announced the completion of a EUR 21.3 million equity funding with an international investor consortium including: Inventages Venture Capital, Novartis Venture Fund, Roche Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners and Enterprise Ireland. Further information is available at http://www.opsona.com/ .

SOURCE: Opsona Therapeutics




        
        Opsona Therapeutics 
        Martin Welschof (CEO) 
        telephone: + 35316770223 
        e-mail: 
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 
        



Copyright Business Wire 2012

...

 
Concerns over wait list for kidney transplants in the NT - ABC Online

MARK COLVIN: A renal health worker in the Northern Territory says it amounts to "institutionalised racism."

A review of organ donation waiting lists has revealed that just 1 per cent of dialysis patients in the Northern Territory are listed for a life-saving kidney. That compares to far higher rates in other states and the ACT.

The research confirms long-standing anecdotal accounts of inequality between states and territories over organ transplants.

The Federal Government's Parliamentary Secretary for Health, Catherine King, says the Northern Territory figures are concerning but believes there have been recent improvements.

Bronwyn Herbert reports.

BRONWYN HERBERT: Aboriginal and Torres Strait Islanders are almost 30 times more likely to get end stage kidney disease than other sections of Australian society.

Many hope to get off dialysis and have a life-saving transplant.

In the Northern Territory more than 400 patients are on dialysis but just a few are on the official transplant waiting list.

Statistics like these are only too familiar to Sarah Brown, a health worker who manages the Western Desert Dialysis mob, based in central Australia.

SARAH BROWN: There's well over 200 people on dialysis in central Australia. Most of those are on haemodialysis which means that people need dialysis three times a week.

So for the majority of people they have to move from their bush communities to Alice Springs to get treatment and it's incredibly difficult for them to get home to see their family and visit country and teach their grandkids.

BRONWYN HERBERT: Patients like 52-year-old Indigenous man, Toby Farmer, who's been on dialysis for almost a decade.

TOBY FARMER: When your kidney, you can't stay one place, no good. Sad, you know? It's sad for us. Like you go three days a week, spent five hours in the dialysis, when they put a needle through you. Five hours. No good.

BRONWYN HERBERT: Transplant physician, Professor Bruce Pussell, from the University of New South Wales, collated the latest publicly available data between 2005 and 2009 on wait lists for kidney transplants.

He says the findings show some disturbing features have emerged.

BRUCE PUSSELL: There's a very low proportion in the Northern Territory. The reason maybe that people of Aboriginal and Torres Strait Islander origin may not be getting listed; they're well over-represented compared to the rest of Australia in terms of dialysis and they're under-represented compared with transplantation prevalence.

BRONWYN HERBERT: The data shows that in the Northern Territory, just three out of more than 400 dialysis patients are on the official waitlist for a kidney.

That's compared to 38 per cent in the Australian Capital Territory.

Sarah Brown says many of her patients mistakenly think they are on the list.

SARAH BROWN: And so often people don't understand what the process is. So someone might say I think I'm on that list but I might be way down the list. But in fact they're not on the active transplant list at all.

It's institutional racism in a way because the system is set up for a literate, numerate person who's had education, understands and follows doctors' instructions and doesn't have all these other cultural priorities.

It's two health systems which collide.

BRONWYN HERBERT: Dr Greg Perry is the director of the Northern Territory renal services.

GREG PERRY: Well look it is a very low figure and it's much lower than other states and the ACT in Australia.

It's a painful fact and patients in the Territory have got reasons for why, you know, so few numbers are on the waiting list for a kidney transplant. It has to deal with the medical issues that they've got; the issues that they would have if they went on to have a successful kidney transplant.

Many of our folk would perhaps run into more complications if they received a successful kidney transplant. It's also got to do with the remoteness of many of our patients and they live out in communities.

BRONWYN HERBERT: Some Northern Territory health workers that I've spoken to amount this to institutionalised racism; the degree of difference between what's happening in the Territory and other states.

What do you say to that?

GREG PERRY: Well look that's a term that's thrown around. It's very easy to use but it's certainly not my experience and I can assure you, and all your listeners, that we are busting our gut to help people move forward to transplantation.

BRONWYN HERBERT: Professor Rowan Walker is the president-elect of the Australia New Zealand Society of Nephrology.

ROWAN WALKER: I think the potential is there for equality. How it actually pans out I think has the potential to be somewhat different.

BRONWYN HERBERT: The national body responsible for organ transplants and donations is the Australian Organ and Tissue Authority.

Catherine King is the Federal Government's Parliamentary Secretary for Health and is responsible for the authority.

CATHERINE KING: There certainly is a disparity in the proportion of young dialysis patients who are making it onto a waiting list.

There's been some improvement in terms of NT, what's happening there. The data on which the article was based is 2005 to 2009 data and there's actually been improvements on the number of certainly Indigenous people getting on the waiting lists in the Northern Territory since that time.

So there's actually been some improvements made.

BRONWYN HERBERT: On average, one person dies every week in Australia while waiting for a kidney transplant. Without hard figures, those who want to get on to the waiting list, and those who are already waiting, may well remain sceptical about promises of improvement.

MARK COLVIN: Bronwyn Herbert with that report.

...

 
'My life would be massively affected by Oaklands estate', says kidney patient - This is Surreytoday

A KIDNEY patient says she faces having her life turned upside down if a controversial 161-home development goes ahead opposite her home.

Grandmother-of-two Miriam Hills takes 18 pills a day to try to keep her condition at bay.

  1. ?Miriam Hills says she faces severe disruption if the Oaklands development goes ahead

    Miriam Hills says she faces severe disruption if the Oaklands development goes ahead

  2. ?'My life would be massively affected by Oaklands estate', says kidney patient - This is Surreytoday

    Miriam Hills faces huge disruption

But Mrs Hills, 53, of Coulsdon Road in Caterham, has been getting worse, meaning that dialysis is now the only answer.

Fifty yards from her front door is the former Oaklands mental health care site – which faces partial demolition to make way for the proposed housing estate, if Tandridge District Council gives it the go-ahead.

This would mean major upheaval for Mrs Hills, a part-time book-keeper.

She said: "One of my kidneys is only functioning 15 per cent efficiently, meaning I am often sick, can't walk far because I get exhausted and suffer regular stomach disorders.

"I also suffer from diabetes, which makes my kidney condition worse."

Mrs Hills said she has been told by specialists at St Helier Hospital in Carshalton that she will need dialysis within months.

But when she informed them of the possibly imminent development across the road, Mrs Hills said she was told that home dialysis would be out of the question – because sterile, dust-free conditions are essential.

She told the Mirror: "I know a lot of local people are very much against the size of this planned development. But any development will affect me massively.

"I will have no alternative but to travel back and forth to St Helier three times per week for four to eight hours' dialysis.

"It will completely disrupt my life.

"Far too much housing is being packed into Caterham."

A spokeswoman from the National Kidney Federation confirmed Mrs Hills's fears. She said: "If there is any risk of dust flying around in the atmosphere, it would be totally unrealistic to proceed with dialysis treatment.

"Having to put a tube in your stomach for dialysis treatment requires a sterile environment, away from any threat of germs and contamination."

An infection can result in severe abdominal pain, nausea, vomiting and fever.

St Helier Hospital said it could not comment on an individual case.

...

 
Long-term graft-versus-tumor effect following reduced intensity hematopoietic ... - UroToday

Canadian Urological Association (CUA)

65th Annual Meeting

June 27 - 29, 2010

Delta Prince Edward Hotel
Charlottetown, PEI Canada

...

 
<< Start < Prev 441 442 443 444 445 446 447 448 449 450 Next > End >>

Page 449 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.